Tag: IR

DENVER, July 21, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of June 30, 2025, was $22.22.

SAN JUAN CAPISTRANO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it expects to issue its second quarter 2025 financial results on Thursday, July 24, 2025.

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ225.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

LITTLE ROCK, Ark., July 21, 2025 (GLOBE NEWSWIRE) -- Westrock Coffee Company (NASDAQ: WEST) ("Westrock Coffee" or the “Company") today announced that it will report its second quarter 2025 results on Thursday, August 7, 2025 after market close. The announcement will be followed by a live earnings conference call at 4:30 p.m. ET.

Restruktūrizuojamos AUGA group, AB (kodas 126264360, buveinės adresas Konstitucijos pr. 21C, Vilnius, toliau - Bendrovė) valdybos iniciatyva ir sprendimu 2025 m. rugpjūčio 12 d. 10:00 val. šaukiamas Bendrovės visuotinis akcininkų susirinkimas, kuriame Bendrovės akcininkai balsuos dėl pritarimo Bendrovės restruktūrizacijos plano projektui (toliau – Susirinkimas).

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra^® for men - in a proprietary topical formulation demonstrated to work where women need it most

Klaipėdos miesto savivaldybė išdavė statybą leidžiantį dokumentą naujam pastatui, kuris bus statomas šalia prekybos ir pramogų centro „Akropolis“. Modernus, 3,5 tūkst. kv. metrų vieno aukšto pastatas su atskiru įėjimu iškils šiaurinėje prekybos ir pramogų centro pusėje, šalia 3-iojo įėjimo.

KPN has repurchased 1,533,000 KPN ordinary shares in the period from 14 July to 18 July 2025. The shares were repurchased at an average price of € 4.09 per share for a total consideration of € 6.3m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders.

High-integrity carbon removal credits will be used to support buyer’s decarbonization and to mitigate corporate travel emissions

New York, N.Y., July 21, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced it will host its third fiscal quarter financial results and business update webcast on Thursday, August 14, 2025, at 5:00 p.m. ET.